Dr. Saumilkumar S. Karavadia, MD

Dr. Karavadia practices at Advanced Urology Institute in Oxford, Florida.

Dr. Karavadia's NPI, 1376747162, was assigned on June 13, 2007. Dr. Karavadia graduated from University of Missouri School of Medicine in 2006. Dr. Karavadia holds Florida license ME116886.

Dr. Karavadia's primary practice is Advanced Urology Institute, at 12109 County Rd 103, Oxford, FL 34484 in Sumter County. The practice phone is (352) 391-6494.

Dr. Karavadia's primary practice is Advanced Urology Institute in Oxford, Florida. Dr. Karavadia is also affiliated with AdventHealth Ocala. The medical group on file is Advanced Urology Institute. Dmand AI also links Dr. Karavadia to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karavadia practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Karavadia's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Karavadia is board certified in urology by the American Board of Urology. Dmand AI has Dr. Karavadia's licenses on file in 2 states: Florida and Arkansas.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and pelvic prolapse among the conditions Dr. Karavadia treats.

CMS data shows 15,653 Medicare services from Dr. Karavadia across 36 procedure codes in 2024, for 1,430 Medicare patients. Medicare paid $449,397 for them.

CMS counts 1,430 Medicare patients who saw Dr. Karavadia in 2024. The largest group is 75 to 84, with 736 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Karavadia's median patient age at 76, with 24% women.

In 2024, Dr. Karavadia wrote 3,600 Medicare Part D claims for 1,033 patients. 83% of them were for generic drugs. CMS names the drug for 3,454 of them, across 35 drugs with 11 or more claims each, at $3,905,315 in total drug cost. In 2023, CMS named 3,663 claims across 38 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Karavadia for performance year 2024, reported as part of a group. Dr. Karavadia accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 14 procedures of prostate resection by Dr. Karavadia, more than 69% of the clinicians it reports for that procedure.

CMS Open Payments shows 797 general payments to Dr. Karavadia from 64 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. Astellas Pharma US Inc paid the most, $51,112.

Dr. Karavadia graduated from University of Missouri School of Medicine in 2006.

Dr. Karavadia is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.